Pharmacist-led medication reviews in pre-dialysis and dialysis patients

被引:8
作者
van Berlo-van de Laar, Inge R. F. [1 ]
Sluiter, Henk E. [2 ]
Riet, Esther van 't [3 ]
Taxis, Katja [4 ]
Jansman, Frank G. A. [1 ,4 ]
机构
[1] Deventer Hosp, Dept Clin Pharm, Nico Bolkesteinlaan 75, NL-7416 SE Deventer, Netherlands
[2] Deventer Hosp, Dept Internal Med, Nico Bolkesteinlaan 75, NL-7416 SE Deventer, Netherlands
[3] Deventer Hosp, Dept Res & Innovat, Nico Bolkesteinlaan 75, NL-7416 SE Deventer, Netherlands
[4] Univ Groningen, Groningen Res Inst Pharm GRIP, Unit PharmacoTherapy Epidemiol & Econ, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands
关键词
Medication reconciliation; Clinical pharmacy service; Pharmaceutical care; Medication error; Dialysis; CHRONIC KIDNEY-DISEASE; OUTPATIENT HEMODIALYSIS UNIT; PHARMACEUTICAL CARE; THERAPY MANAGEMENT; ELDERLY-PATIENTS; RECONCILIATION; INTERVENTIONS; POLYPHARMACY; IMPACT; HOSPITALIZATION;
D O I
10.1016/j.sapharm.2020.02.006
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Pre-dialysis and dialysis patients are at risk for drug related problems (DRPs) due to a high incidence of comorbidities. Pharmacist-led medication reviews might reduce the number of DRPs. Objectives: The aim of this study was to evaluate pharmacist-led medication reviews in pre-dialysis and dialysis patients by determining the number and type of DRPs, nephrologist acceptance of pharmacist interventions and time investment. Methods: From September 2017 until December 2018, pharmacist-led medication reviews were performed on pre-dialysis and dialysis patients. DRPs (medication discrepancies, prescribing issues related to drug and dose selection, drug use problems) were identified using the pharmacists' expert opinion and the STOPP/START criteria. Number and type of accepted pharmacist interventions, sustainability of interventions after at least 1 month and time investment were determined. Practical barriers in the process were appraised. Results: One-hundred twenty five patients were reviewed: 37 pre-dialysis and 88 dialysis patients. In 100 (80%) patients 277 medication discrepancies were identified of which 224 (81%) were accepted by the nephrologist. Pharmacists suggested 422 interventions concerning drug or dose selection for 115 patients; 106 interventions were accepted by the nephrologist, which resulted in 60 patients having medication changed. Ninety percent of those changes remained implemented on follow-up after at least 1 month. In 46 (37%) patients, the clinical pharmacist detected DRPs concerning the drug use process and performed patient counseling. The average time investment was 85 min per patient for the clinical pharmacist and 15 min for the nephrologist. Besides time investment, unclear responsibility for medication management due to multiple prescribers was an important barrier in the process and the main reason for nephrologists to reject pharmacist interventions. Conclusion: Pharmacist-led medication reviews in pre-dialysis and dialysis patients led to medication changes in half of the patients. However, efficiency should be improved before adopting pharmacist-led medication reviews into clinical practice.
引用
收藏
页码:1718 / 1723
页数:6
相关论文
共 42 条
  • [1] Abramsson L, 2019, RES SOC ADM PHARM
  • [2] Clinical pharmacy practice in the care of Chronic Kidney Disease patients: a systematic review
    Al Raiisi, Fatma
    Stewart, Derek
    Fernandez-Llimos, Fernando
    Salgado, Teresa M.
    Mohamed, Moustafa Fahmy
    Cunningham, Scott
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (03) : 630 - 666
  • [3] [Anonymous], DEV EV COMPL INT
  • [4] [Anonymous], 2012, DUTCH MULTIDISCIPLIN
  • [5] Impact of Pharmacist-Managed Erythropoiesis-Stimulating Agents Clinics for Patients With Non-Dialysis-Dependent CKD
    Aspinall, Sherrie L.
    Cunningham, Francesca E.
    Zhao, Xinhua
    Boresi, Joy S.
    Tonnu-Mihara, Ivy Q.
    Smith, Kenneth J.
    Stone, Roslyn A.
    Good, Chester B.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 60 (03) : 371 - 379
  • [6] Development of an Aggregated System for Classifying Causes of Drug-Related Problems
    Basger, Benjamin J.
    Moles, Rebekah J.
    Chen, Timothy F.
    [J]. ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 405 - 418
  • [7] A FORMAL MEDICATION RECONCILIATION PROGRAMME IN A HAEMODIALYSIS UNIT CAN IDENTIFY MEDICATION DISCREPANCIES AND POTENTIALLY PREVENT ADVERSE DRUG EVENTS
    Chan, Winnie W. Y.
    Mahalingam, Geetha
    Richardson, Robert M. A.
    Fernandes, Olavo A.
    Battistella, Marisa
    [J]. JOURNAL OF RENAL CARE, 2015, 41 (02) : 104 - 109
  • [8] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [9] Outcomes of pharmacist-provided medication review in collaborative care for adult Singaporeans receiving hemodialysis
    Chia, Bih Yee
    Cheen, McVin Hua Heng
    Gwee, Xin Yi
    Chow, Melissa Mee Yin
    Khee, Giat Yeng
    Ong, Wan Chee
    Choong, Hui Lin
    Lim, Paik Shia
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (05) : 1031 - 1038
  • [10] The use of pharmaceutical care to improve health-related quality of life in hemodialysis patients in Iran
    Dashti-Khavidaki, Simin
    Sharif, Zahra
    Khalili, Hossein
    Badri, Shirinsadat
    Alimadadi, Abbas
    Ahmadi, Farrokhlegha
    Gatmiri, Mansoor
    Rahimzadeh, Soraya
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (02) : 260 - 267